Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...

Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). But which of these two stocks presents ...

Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

*Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the ...

Asian stock markets rebounded from Monday's sell-off, as traders looked for bargains and weighed signs that China's huge industrial base may be weathering trade tensions and the nation's property woes ...